Chagas Disease: Criteria of Cure and Prognosis

Memorias do Instituto Oswaldo Cruz

Volumn 94, Issue SUPPL. 1, 1999, Pages 357-362

  Gontijo, Eliane Dias ^a   Galvão, Lúcia M C ^b   Eloi Santos, Silvana ^b  

^a Depto de Med Preventiva e Social   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chagas disease; Cure; Prognosis

Indexed keywords

ANTITRYPANOSOMAL AGENT;

CHAGAS DISEASE; HUMAN; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; REVIEW;

CHAGAS DISEASE; HUMANS; MIDDLE AGED; PROGNOSIS; TRYPANOCIDAL AGENTS;

EID: 0033256226     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761999000700069     Document Type: Article

References (45)

1. Almeida IC, Krautz G.M, Krettli AU, Travassos LR 1993. Glycoconjugates of Trypanosoma cruzi: a 74 kDa antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal 7: 307-316.
2. Andrade SG, Stocker-Guerret S, Pimentel AS et al. 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi under specific chemoterapy. Mem Inst Oswaldo Cruz 86: 187-200.
3. Araújo FG 1986. Analysis of Trypanosoma cruzi antigens bound by specific antibodies and by antibodies to related tripanosomatids. Infect Immun 53: 179-185.
4. Avila H, Borges-Pereira J, Thiemann O, De Paiva E, Degrave W, Morel CM, Simpson L 1993. Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J Clin Microbiol 31: 2421-2426.
5. Britto C, Cardoso MA, Vanni CMM, Hasslocher-Moreno A, Xavier S, Oeleman W, Santoro A, Pimimez C, Morel CM, Wincker P 1995. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evolution. Parasitology 110: 241-247.
6. Cançado JR 1980. Forma aguda da doença de Chagas no Brasil. Rev Assoc Med Bras 26: 285-288.
7. Cançado JR 1981. Standardization of protocols for chemotherapy of Chagas disease, p. 15. In Steering Committee on Chemotherapy and Parasitology, World Health Organization, Washington.
8. Cançado R, Brener Z 1979. Terapéutica. In Z Brener, Z Andrade (eds) Trypanosoma cruzi e Doença de Chagas, Guanabara Koogan, Rio de Janeiro.
9. Castro CN, Alves MT, Macedo VO 1983. Importância da repetição do xenodiagnóstico para avaliação da parasitemia na fase crônica da doença de Chagas. Rev Soc Bras Med Trop 16: 98-103.
10. Cerisola JA, Russo MC, Prado C, Yozami LBJ, Rohweder RW 1972. Estudio comparativo de diversos métodos parasitológicos en la enfermedad de Chagas aguda, p. 97-100. In Protozoologia Simposio Internacional sobre Enfermedad de Chagas, Buenos Aires.
11. Chiari E, Dias JCP, Lana M, Chiari CA 1989. Hemocultures for the parasitological diagnostic of human chronic Chagas disease. Rev Soc Bras Med Trop 22: 19-23.
12. Chiller TM, Samudio MA, Zoulek G 1990. IgG antibody reactivity with Trypanosoma cruzi and Leishmania antigens in sera of patients with Chagas disease and leishmaniasis. Am J Trop Med Hyg 43: 650-656.
13. Coura J Rodrigues, Abreu Laércio L, Willcox Henry PF, Petana W 1997. Estudo comparativo controlabo com emprego de Benznidazole. Nifurtimox e placedo na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. Avaliação preliminar. Rev Soc Bras Med Trop 30: 139-144.
14. Cunha-Neto E, Coelho VPC, Guilherme L, Fiorelli A, Stolf N, Kalil J 1996. Autoimmunity in Chagas disease: identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient. J Clin Investigation 98: 1709-1712.
15. Dutra WO, Martins-Filho O, Cançado JR, Dias JCP, Brener Z, Freeman Jr GL, Colley DG, Gazzinelli G, Parra JC 1994. Activated T and B lymphocytes in peripheral blood of patients with Chagas disease. Int Immunol 6: 499.
16. Ferreira HO 1970. Treatment of the indetermined form of Chagas disease with nifurtimox and benznidazole. Rev Soc Bras Med Trop 23: 209-211.
17. Fragata-Filho AA, Boainaim E, Dias da Silva MA 1995. Validade do tratamento etiológico na fase crônica da doença de Chagas com benznidazol. Arq Bras Cardiol 65 (Suppl. I): 71.
18. Galvão LMC, Nunes RMB, Cançado JR, Brener Z, Krettli AU 1993. Lytic antibodies titre as means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg. 87: 220-223.
19. Gazzinelli RT, Galvão LMC, Krautz G, Lima APC, Cançado JR, Scharfstein J, Krettli AU 1993. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas disease. Am J Trop Med Hyg 49: 625-635.
20. Gomes ML, Macedo AM, Vago AR, Pena SDJ, Galvão LMC, Chiari E 1998. Trypanosoma cruzi: Optimization of polymerase chain reaction for detection in human blood. Exp Parasitol 88: 28-33.
21. Gomes ML, Galvão LMC, Macedo AM, Pena SDJ, Chiari E 1999. Chagas disease diagnosis: Comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg 60: 205-210.
22. Gomes JAS 1998. Avaliação Imunológica de Pacientes Chagásicos Submetidos a Quimioterapia Durante a Fase Aguda da Infecção Há Aproximadamente 14-30 Anos. MSc Thesis, Universidade Federal de Minas Gerais, Belo Horizonte, 99 pp.
23. Higushi ML 1995. O parasita e a patogenia da forma crônica da doença de Chagas. Arq Bras Cardiol 64: 251-254.
24. Kalil R, Bocchi E, Rosemberg L 1993. Ressonância magnética para avaliação de processo inflamatório de miocárdio da doença de Chagas. Rev Soc Cardiol Estado São Paulo 3 (Suppl.): 54.
25. Krautz GM, Coutinho, MG, Galvão LMC, Cançado JR, Krettli AU 1994. Soluble antigens released by Trypanosoma cruzi trypomastigotes used in ELISA to detect cure in chagasic patients following specific treatment. Rev Soc Bras Med Trop 27: 199-207.
26. Krautz GM, Galvão LMC, Cançado JR, Guevara-Espinosa A, Ouaissi A, Krettli AU 1995. Use of 24kDa Trypanosoma cruzi recombinant protein to monitor cure of Chagas disease. J Clin Microbiol 33: 2086-2090.
27. Krettli AU, Brener Z 1982. Resistence against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol 128: 2008-2012.
28. Krettli AU, Cançado JR, Brener Z 1982. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas disease. Trans R Soc Trop Med Hyg 76: 334-340.
29. Krettli AU, Cançado JR, Brener Z 1984. Criterion on cure of human Chagas disease after specific chemotherapy: recent advances. Mem Inst Oswaldo Cruz 79: 157-164.
30. Luz ZMP, Coutinho MG, Cançado JR, Krettli AU 1994. Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease. Rev Soc Bras Med Trop 27: 143-148.
31. Macedo V, Silveira CA 1987. Perpectivas da terapêutica especifica da doença de Chagas na forma indeterminada. Rev Soc Bras Medicina Tropical 20 (Suppl. 2) 24-26.
32. Manzullo EC, Danaidon MA, Libonatti O, Rozlosnik J 1982. Estudio Longitudinal de la Cardiopatia Chagasica Cronica, Fac. Ciencias Medicas, Buenos Aires, 141 pp.
33. Murta ACM, Persechini PM, Souto-Padron T, de Souza W, Guimarães J, Scharfstein J 1990. Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cystein proteinase. Mol Biochem Parasitol 43: 27-46.
34. Martins-Filho OA, Pereira MES, Carvalho JF, Cançado JR, Brener Z 1995. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas disease. Clin Diag Lab Immunol 2: 569-573.
35. Ouaissi A, Aguirre T, Plumas-Marty B, Piras M, Schoveck R, Gras-Masse H, Taibi A, Loyens M, Tartar A, Capron A, Piras R 1992. Cloning and sequencing of a 24 kDa Trypanosoma specific antigen released in association with membrane vesicles and defined by monoclonal antibody. Biol Cell 75: 11-17.
36. Rassi A, Luquetti A 1996. Tratamento especifico da doença de Chagas. Métodos laboratoriais especificos. Rev Soc Bras Med Trop 29 (Supl. 2): 63-65.
37. Reed SG 1998. Immunology of Trypanosoma cruzi infections. Chem Immunol 70: 124-143
38. Reis DD, Jones EM, Tostes S, Lopes ER, Chapadeiro E, Gazzinelli G, Colley DG, McCurley T 1993. Expression of major histoaompatibility complex antigens and adhesion molecules in hearts of patients with chronic Chagas disease. Am J Trop Med Hyg 49: 192-196.
39. Reunião Anual sobre Pesquisa Aplicada em Doença de Chagas. Tratamento especifico 1986. Rev Soc Bras Med Trop 19: 102-103.
40. Segura MA, Molina de Raspi E, Basombrio MA 1994. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice, after late trypanomicidal treatment. Mem Inst Oswaldo Cruz 89: 213-16.
41. Taibi A, Plumas-Marty B, Guevara-Espinosa A, Schoneck R, Pessoa H, Loyens M, Piras R, Aguirre T, Gras-Masse H, Bossus M 1993. Trypanosoma cruzi: immunity induced in mice and rats by trypomastigote excretory-secretary antigens and identification of a peptide sequence containing a T cell epitope with protective activity. Immunol 151: 2676-2689.
42. Tarleton RL, Zhang L, Dowons MO 1997. "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci USA 94: 3932-3937.
43. Toledo MJ, Guilherme AL, Silva JC 1997. Trypanosoma cruzi chemotherapy with benznidazol in mice inoculated with strains from Paraná state and different endemic areas of Brasil. Rev Inst Med Trop São Paulo 39: 283-290.
44. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoya C, Molina J, Piras M, Piras R, Perez N, Wincker P, Loenberg D 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42: 1771-1777.
45. Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic Chagas disease with benzonidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.